

Nicole M Verrills

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6173143/publications.pdf>

Version: 2024-02-01

28
papers

1,276
citations

567281

15
h-index

580821

25
g-index

32
all docs

32
docs citations

32
times ranked

1650
citing authors

#	ARTICLE	IF	CITATIONS
1	PP2A activation targets AML stem cells. <i>Blood</i> , 2022, 139, 1267-1269.	1.4	0
2	Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia. <i>Leukemia</i> , 2021, 35, 1782-1787.	7.2	22
3	Ppp2r2a Knockout Mice Reveal That Protein Phosphatase 2A Regulatory Subunit, PP2A-B55 $\hat{\pm}$, Is an Essential Regulator of Neuronal and Epidermal Embryonic Development. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 358.	3.7	13
4	Shwachmanâ€“Bodianâ€“Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia. <i>Leukemia</i> , 2020, 34, 3393-3397.	7.2	14
5	Phosphoproteomics Uncovers Synergy between DNA-PK and FLT3 Inhibitors in Acute Myeloid Leukaemia. <i>Blood</i> , 2020, 136, 12-12.	1.4	2
6	Comment on â€œPP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemiaâ€œ. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	6
7	Cellâ€“Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700121.	1.6	11
8	Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3198.	4.1	45
9	Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 431-447.	5.0	15
10	Functional importance of PP2A regulatory subunit loss in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 117-131.	2.5	21
11	A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. <i>Anti-Cancer Drugs</i> , 2016, 27, 560-568.	1.4	15
12	Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 4605-4616.	2.8	24
13	Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. <i>Oncotarget</i> , 2016, 7, 47465-47478.	1.8	39
14	Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolin. <i>Scientific Reports</i> , 2015, 5, 10063.	3.3	29
15	Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1720-1727.	2.9	32
16	Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation. <i>Cellular Signalling</i> , 2010, 22, 1882-1890.	3.6	12
17	Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers. <i>Cancer Research</i> , 2010, 70, 5438-5447.	0.9	119
18	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosomeâ€“positive acute lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2007, 117, 2408-2421.	8.2	308

#	ARTICLE	IF	CITATIONS
19	Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia – An in vivo study. <i>Proteomics</i> , 2006, 6, 1681-1694.	2.2	84
20	Mast cell function: Regulation of degranulation by serine/threonine phosphatases. , 2006, 112, 425-439.		31
21	Clinical proteomics: present and future prospects. <i>Clinical Biochemist Reviews</i> , 2006, 27, 99-116.	3.3	55
22	Microtubule Alterations and Mutations Induced by Desoxyepothilone B. <i>Chemistry and Biology</i> , 2003, 10, 597-607.	6.0	106
23	Proteome Analysis of Vinca Alkaloid Response and Resistance in Acute Lymphoblastic Leukemia Reveals Novel Cytoskeletal Alterations. <i>Journal of Biological Chemistry</i> , 2003, 278, 45082-45093.	3.4	79
24	Drug resistance mechanisms in cancer cells: a proteomics perspective. <i>Current Opinion in Molecular Therapeutics</i> , 2003, 5, 258-65.	2.8	9
25	Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels. <i>Electrophoresis</i> , 2000, 21, 1094-1103.	2.4	144
26	Cross-matching marsupial proteins with eutherian mammal databases: Proteome analysis of cells from UV-induced skin tumours of an opossum (<i>Monodelphis domestica</i>). <i>Electrophoresis</i> , 2000, 21, 3810-3822.	2.4	15
27	Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels. <i>Electrophoresis</i> , 2000, 21, 1094-1103.	2.4	3
28	The microbial proteome database – an automated laboratory catalogue for monitoring protein expression in bacteria. <i>Electrophoresis</i> , 1999, 20, 3580-3588.	2.4	17